April 27, 2015.
Sophia Antipolis, France.
Nicox S.A. (Euronext Paris: FR0000074130, COX), the international ophthalmic company, today announced the implementation of a liquidity contract.
As from April 27, 2015, and for a period of one year which is automatically renewable, Nicox has entrusted Gilbert Dupont with the implementation of a liquidity contract that complies with the code of ethics issued by the AMAFI and approved by the French Autorité des Marchés Financiers (AMF) on March 21, 2011.
The following resources have been credited to the liquidity account for the implementation of this contract:
€1,000,000 in cash
...................................
About Nicox
Nicox (Bloomberg: COX:FP, Reuters: NCOX.PA) is an international commercial-stage company focused on the ophthalmic market. With a heritage of innovative R&D, business development and marketing expertise, we are building a diversified portfolio of ophthalmic products that can help people to enhance their sight.
Nicox's advanced pipeline features two pre-NDA candidates (Vesneo(TM) for glaucoma, partnered with Bausch + Lomb / Valeant and AC-170 for allergic conjunctivitis) as well as two pre-MAA candidates (AzaSite® for bacterial conjunctivitis and BromSite(TM) for pain and inflammation after cataract surgery). The Group operates directly in six countries, including the United States. It has proprietary commercial operations in Europe's five largest markets complemented by an expanding international network of distributors.
Nicox is headquartered in France and has more than 120 staff worldwide. It is listed on Euronext Paris (Category B: Mid Caps) and is part of the CAC Healthcare, CAC Pharma & Bio and Next 150 indexes.
For more information on Nicox, its commercial products or pipeline, please visit www.nicox.com.
| Upcoming events | ||
| Financial and business conferences | ||
| May 21 | Gilbert Dupont Forum Santé | Paris, France |
| June 16 | Gilbert Dupont Forum Small & Midcaps | Paris, France |
| June 25 | Kepler Biotech Day | Paris, France |
| Scientific conferences | |||
| May 3-7 | Association for Research in Vision and Ophthalmology (ARVO) | Denver, United States | |
| May 9-12 | Société Française d'Ophtalmologie (SFO) | Paris, France | Booth PO2 |
| May 14-16 | Sociedad Española de Cirugía Ocular Implanto Refractiva (SECOIR) | Gran Canaria, Spain | Booth tbc |
| May 19-21 | Royal College of Ophthamologists (RCO) | Liverpool, United Kingdom | Booth 33 |
| June 6-9 | European Society of Ophthalmology (SOE) | Vienna, Austria | |
| June 28-30 | MaculArt | Paris, France | Booth tbc |
| Analyst coverage | ||
| Bryan, Garnier & Co | Hugo Solvet | Paris |
| Stifel | Max Herrmann | London |
| Invest Securities | Martial Descoutures | Paris |
This press release contains certain forward-looking statements. Although the Company believes its expectations are based on reasonable assumptions, these forward-looking statements are subject to numerous risks and uncertainties, which could cause actual results to differ materially from those anticipated in the forward-looking statements.
Risks factors which are likely to have a material effect on Nicox's business are presented in the 4th chapter of the 'Document de référence, rapport financier annuel et rapport de gestion 2014' filed with the French Autorité des Marchés Financiers (AMF) on April 10, 2015, which is available on Nicox's website (www.nicox.com).
